Intensive radiation therapy concurrent with up to 7-week continuous- infusion paclitaxel for locally advanced solid tumors

Phase I studies

D. I. Rosenthal, O. Okani, J. M. Truelson, H. Fathallah-Shaykh, F. M. Vuitch, A. F. Gazdar, J. Griener, M. Landay, D. Mendelsohn, J. Tourville, L. Hamilton, K. Y. Orr, J. McWhorter

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Patients with locally advanced solid tumors of the lung, head and neck, and malignant astrocytomas usually succumb to their disease despite aggressive standard therapy. Laboratory data suggest that the addition of 1.0 to 10 nmol/L paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a microtubule stabilizing drug, to radiation therapy may result in significant radiation sensitization, perhaps due to accumulation of cells at G2/M. Relatively low concentrations (1.0 to 10 nmol/L) appear to be optimal for direct cytotoxicity and radiosensitization in vitro. Within this dose range, more prolonged exposure seems to result in higher response rates. The phase 1 trials reported here are designed to test the combination of paclitaxel, administered by continuous intravenous infusion (24 hours a day, 7 days a week), and standard, curative-intent radiation therapy. The ultimate goal of this study is to improve local and systemic control and survival for patients with these three tumor types. To date, 39 evaluable patients are enrolled in this study; there has been no dose-limiting toxicity up to 6.5 mg/m2/d. Observed toxicities include anemia, lymphopenia, mucositis, and cutaneous toxicities.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number1 SUPPL. 2
StatePublished - 1997

Fingerprint

Paclitaxel
Radiotherapy
Neoplasms
Mucositis
Lymphopenia
Astrocytoma
Intravenous Infusions
Microtubules
Anemia
Neck
Head
Radiation
Lung
Skin
Survival
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Intensive radiation therapy concurrent with up to 7-week continuous- infusion paclitaxel for locally advanced solid tumors : Phase I studies. / Rosenthal, D. I.; Okani, O.; Truelson, J. M.; Fathallah-Shaykh, H.; Vuitch, F. M.; Gazdar, A. F.; Griener, J.; Landay, M.; Mendelsohn, D.; Tourville, J.; Hamilton, L.; Orr, K. Y.; McWhorter, J.

In: Seminars in Oncology, Vol. 24, No. 1 SUPPL. 2, 1997.

Research output: Contribution to journalArticle

Rosenthal, DI, Okani, O, Truelson, JM, Fathallah-Shaykh, H, Vuitch, FM, Gazdar, AF, Griener, J, Landay, M, Mendelsohn, D, Tourville, J, Hamilton, L, Orr, KY & McWhorter, J 1997, 'Intensive radiation therapy concurrent with up to 7-week continuous- infusion paclitaxel for locally advanced solid tumors: Phase I studies', Seminars in Oncology, vol. 24, no. 1 SUPPL. 2.
Rosenthal, D. I. ; Okani, O. ; Truelson, J. M. ; Fathallah-Shaykh, H. ; Vuitch, F. M. ; Gazdar, A. F. ; Griener, J. ; Landay, M. ; Mendelsohn, D. ; Tourville, J. ; Hamilton, L. ; Orr, K. Y. ; McWhorter, J. / Intensive radiation therapy concurrent with up to 7-week continuous- infusion paclitaxel for locally advanced solid tumors : Phase I studies. In: Seminars in Oncology. 1997 ; Vol. 24, No. 1 SUPPL. 2.
@article{92cd3009cc7a4bfca2554e60c1704302,
title = "Intensive radiation therapy concurrent with up to 7-week continuous- infusion paclitaxel for locally advanced solid tumors: Phase I studies",
abstract = "Patients with locally advanced solid tumors of the lung, head and neck, and malignant astrocytomas usually succumb to their disease despite aggressive standard therapy. Laboratory data suggest that the addition of 1.0 to 10 nmol/L paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a microtubule stabilizing drug, to radiation therapy may result in significant radiation sensitization, perhaps due to accumulation of cells at G2/M. Relatively low concentrations (1.0 to 10 nmol/L) appear to be optimal for direct cytotoxicity and radiosensitization in vitro. Within this dose range, more prolonged exposure seems to result in higher response rates. The phase 1 trials reported here are designed to test the combination of paclitaxel, administered by continuous intravenous infusion (24 hours a day, 7 days a week), and standard, curative-intent radiation therapy. The ultimate goal of this study is to improve local and systemic control and survival for patients with these three tumor types. To date, 39 evaluable patients are enrolled in this study; there has been no dose-limiting toxicity up to 6.5 mg/m2/d. Observed toxicities include anemia, lymphopenia, mucositis, and cutaneous toxicities.",
author = "Rosenthal, {D. I.} and O. Okani and Truelson, {J. M.} and H. Fathallah-Shaykh and Vuitch, {F. M.} and Gazdar, {A. F.} and J. Griener and M. Landay and D. Mendelsohn and J. Tourville and L. Hamilton and Orr, {K. Y.} and J. McWhorter",
year = "1997",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL. 2",

}

TY - JOUR

T1 - Intensive radiation therapy concurrent with up to 7-week continuous- infusion paclitaxel for locally advanced solid tumors

T2 - Phase I studies

AU - Rosenthal, D. I.

AU - Okani, O.

AU - Truelson, J. M.

AU - Fathallah-Shaykh, H.

AU - Vuitch, F. M.

AU - Gazdar, A. F.

AU - Griener, J.

AU - Landay, M.

AU - Mendelsohn, D.

AU - Tourville, J.

AU - Hamilton, L.

AU - Orr, K. Y.

AU - McWhorter, J.

PY - 1997

Y1 - 1997

N2 - Patients with locally advanced solid tumors of the lung, head and neck, and malignant astrocytomas usually succumb to their disease despite aggressive standard therapy. Laboratory data suggest that the addition of 1.0 to 10 nmol/L paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a microtubule stabilizing drug, to radiation therapy may result in significant radiation sensitization, perhaps due to accumulation of cells at G2/M. Relatively low concentrations (1.0 to 10 nmol/L) appear to be optimal for direct cytotoxicity and radiosensitization in vitro. Within this dose range, more prolonged exposure seems to result in higher response rates. The phase 1 trials reported here are designed to test the combination of paclitaxel, administered by continuous intravenous infusion (24 hours a day, 7 days a week), and standard, curative-intent radiation therapy. The ultimate goal of this study is to improve local and systemic control and survival for patients with these three tumor types. To date, 39 evaluable patients are enrolled in this study; there has been no dose-limiting toxicity up to 6.5 mg/m2/d. Observed toxicities include anemia, lymphopenia, mucositis, and cutaneous toxicities.

AB - Patients with locally advanced solid tumors of the lung, head and neck, and malignant astrocytomas usually succumb to their disease despite aggressive standard therapy. Laboratory data suggest that the addition of 1.0 to 10 nmol/L paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), a microtubule stabilizing drug, to radiation therapy may result in significant radiation sensitization, perhaps due to accumulation of cells at G2/M. Relatively low concentrations (1.0 to 10 nmol/L) appear to be optimal for direct cytotoxicity and radiosensitization in vitro. Within this dose range, more prolonged exposure seems to result in higher response rates. The phase 1 trials reported here are designed to test the combination of paclitaxel, administered by continuous intravenous infusion (24 hours a day, 7 days a week), and standard, curative-intent radiation therapy. The ultimate goal of this study is to improve local and systemic control and survival for patients with these three tumor types. To date, 39 evaluable patients are enrolled in this study; there has been no dose-limiting toxicity up to 6.5 mg/m2/d. Observed toxicities include anemia, lymphopenia, mucositis, and cutaneous toxicities.

UR - http://www.scopus.com/inward/record.url?scp=0031049555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031049555&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL. 2

ER -